FibroGen Appoints David DeLucia as Chief Financial Officer
16 Diciembre 2024 - 7:05AM
FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment
of David DeLucia to Chief Financial Officer (CFO), effective
December 16, 2024. The company previously announced that Juan
Graham would step down on December 15, 2024.
Reporting to Chief Executive Officer Thane
Wettig, DeLucia will lead and oversee FibroGen’s global finance
organization. He has most recently served as FibroGen’s Vice
President, Head of Corporate Financial Planning and Analysis,
Investor Relations, and Treasury.
“Having worked closely with David for the past
two and a half years, I am extremely confident he has the breadth
and depth of experiences and capabilities required to lead our
finance organization and be a key member of our leadership team,”
said Thane Wettig, Chief Executive Officer of FibroGen. “His deep
understanding of all aspects of our business, along with his proven
track record and strategic insights will be invaluable in his new
role as CFO as we advance FG-3246, a first-in-class ADC targeting
CD46, and its companion diagnostic FG-3180, while further building
on the strong performance of roxadustat.”
“I am thrilled to take on the role of CFO at FibroGen and to
help lead the company at this important time,” said DeLucia. “With
our recent transformation into a lean and focused organization, I
believe we are well positioned for an exciting future and look
forward to continued execution on our strategic vision to bring
novel therapies forward for cancer and cancer-related
conditions.”
Mr. DeLucia has nearly 15 years of financial leadership and
experience within the life sciences industry. Prior to joining
FibroGen in 2022, he held positions of increasing responsibility at
TherapeuticsMD, overseeing Financial Planning and Analysis,
Corporate Development, and Investor Relations. Earlier in his
career, he was a buy-side investor at JP Morgan Asset Management,
covering small and mid-cap healthcare companies.
Mr. DeLucia holds the Chartered Financial Analyst® designation
and a dual degree of Bachelor of Business Administration in Finance
& Accounting and Bachelor of Science in Economics from the
University of Michigan - Stephen M. Ross School of Business.
About FibroGen FibroGen, Inc. is a
biopharmaceutical company focused on accelerating the development
of novel therapies at the frontiers of cancer biology. Roxadustat
(爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and
numerous other countries for the treatment of anemia in chronic
kidney disease (CKD) patients on dialysis and not on dialysis.
Roxadustat is in clinical development for chemotherapy-induced
anemia (CIA) and a Supplemental New Drug Application (sNDA) has
been accepted for review by the China Health Authority. FG-3246
(also known as FOR46), a first-in-class antibody-drug conjugate
(ADC) targeting CD46 is in development for the treatment of
metastatic castration-resistant prostate cancer. This program also
includes the development of an associated CD46-targeted PET imaging
agent, FG-3180. In addition, FibroGen’s research and development
portfolio includes two immuno-oncology product candidates for the
treatment of solid tumors. For more information, please visit
www.fibrogen.com.
Forward-Looking Statements This release
contains forward-looking statements regarding FibroGen’s strategy,
future plans and prospects, including statements regarding its
commercial products and clinical programs and those of its
collaboration partners Fortis and UCSF. These forward-looking
statements include, but are not limited to, statements regarding
the potential clinical or commercial success of FibroGen products
and product candidates, and statements about FibroGen’s plans and
objectives. These forward-looking statements are typically
identified by use of terms such as “may,” “will”, “should,” “on
track,” “could,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently.
FibroGen’s actual results may differ materially from those
indicated in these forward-looking statements due to risks and
uncertainties related to the continued progress and timing of its
various programs, including the enrollment and results from ongoing
and potential future clinical trials, and other matters that are
described in FibroGen’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2023, and our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2024, each as filed with the
Securities and Exchange Commission (SEC), including the risk
factors set forth therein. Investors are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this release, and FibroGen undertakes no
obligation to update any forward-looking statement in this press
release, except as required by law.
Contact:David DeLucia, CFAVice President of
Corporate FP&A / Investor Relationsir@fibrogen.com
FibroGen (NASDAQ:FGEN)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
FibroGen (NASDAQ:FGEN)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024